Interventional cardiology 2006;Cardiología intervencionista 2006

Revista Espanola de Cardiologia

Volumn 60, Issue SUPPL. 1, 2007, Pages 19-32

  Hernández Antolín, Rosa Ana ^a   Fernández Vázquez, Felipe ^b   Burgos, José Moreu ^c   Palop, Ramón López ^d  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL DE LEÓN   (Spain)

^c HOSPITAL VIRGEN DE LA SALUD   (Spain)

^d HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

Author keywords

Cellular therapy; Drug eluting stents; Percutaneous coronary intervention; Percutaneous noncoronary intervention; Stents

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CARBOSTENT; CLOPIDOGREL; CYPHER; ENDEAVOUR; EPTIFIBATIDE; EVEROLIMUS; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HEPARIN; HIRULOG; PACLITAXEL; RAPAMYCIN; UNCLASSIFIED DRUG; XIENCE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGIOPLASTY; AORTA STENOSIS; BLOOD CLOT LYSIS; BLOOD VESSEL OCCLUSION; CARDIOVASCULAR DISEASE; CELL THERAPY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; ECHOCARDIOGRAPHY; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; ISCHEMIC HEART DISEASE; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; REVASCULARIZATION; REVIEW; ST SEGMENT ELEVATION; ACUTE DISEASE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; MULTIMODALITY CANCER THERAPY; SYNDROME; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMBINED MODALITY THERAPY; CORONARY DISEASE; CORONARY RESTENOSIS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; SYNDROME;

EID: 34249720694     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13099710     Document Type: Article

References (120)

1. Serruys PW, Ong AT, Van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. 2005;46:575-81.
2. Rodríguez AE, Baldi J, Fernández Pereira C, Navia J, Rodríguez Alemparte M, Delacasa A, et al. Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). J Am Coll Cardiol. 2005;46:582-8
3. Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med. 2005;352:2174-83.
4. Malenka DJ, Leavitt BJ, Hearne MJ, Robb JF, Baribeau YR, Ryan TJ, for the Northern New England Cardiovascular Disease Study Group. Comparing long-term survival of patients with multivessel coronary disease after CABG or PCI: analysis of BARI-like patients in Northern New England. Circulation. 2005;112 9 Suppl:I371-6.
5. López-Palop R, Moreu J, Fernández-Vázquez F, Hernández R. Registro Español de Hemodinámica y Cardiología Intervencionista. XVI Informe Oficial de la Sección de Hemodinámica y Cardiología Intervencionista de la Sociedad Española de Cardiología (1990-2005). Rev Esp Cardiol. 2006;59:1146-64.
6. Kappetein AP, Dawkins KD, Mohr FW, Morice MC, Mack MJ, Russell ME, et al. Current percutaneous coronary intervention and coronary artery bypass grafting practices for three-vessel and left main coronary artery disease. Insights from the SYNTAX run-in phase. Eur J Cardiothorac Surg. 2006;29:486-91.
7. Serruys PW, Ong ATL, Morice MC, De Bruyne B, Colombo A, Macaya C, et al. Arterial Revascularisation Therapies Study. Part II. Sirolimus-eluting stents for the treatment of patients with multivessel de novocoronary artery lesions. Eurointervention. 2005;1:147-56.
8. Vassiliades TA Jr, Douglas JS, Morris DC, Block PC, Ghazzal Z, Rab ST, et al. Integrated coronary revascularization with drug-eluting stents: immediate and seven-month outcome. J Thorac Cardiovasc Surg. 2006;131:956-62.
9. Smith SC, Feldman TE, Hirshfeld JW, Jacobs AK, Kern MJ, King III SB, et al. ACC/AHA/SCAI 2005 Guideline update for Percutaneous Coronary Intervention.: a report of the American College of Cardiology/American Heart Association Task Force on Practice . J Am Coll Cardiol. 2006;47:e1-121.
10. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al. Guías de práctica clínica sobre intervencionismo coronario percutáneo. Rev Esp Cardiol. 2005;58:679-728.
11. Ragosta M, Dee S, Sarembock IJ, Lipson LC, Gimple LW, Powers ER. Prevalence of unfavorable angiographic characteristics for percutaneous intervention in patients with unprotected left main coronary artery disease. Catheter Cardiovasc Interv. 2006;68:357-62.
12. Lee MS, Kapoor N, Jamal F, Czer L, Aragon J, Forrester, et al. Comparison of coronary artery bypass surgery with percutaneous coronary intervention with drug-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol. 2006;47:864-70.
13. Chieffo A, Morici N, Maisano F, Bonizzoni E, Cosgrave J, Montorfano M, et al. Percutaneous treatment with drug-eluting stent implantation versus bypass surgery for unprotected left main stenosis: a single-center experience. Circulation. 2006;113:2542-7.
14. Valgimigli M, Malagutti P, Rodríguez-Granillo GA, García-García HM, Polad J, Tsuchida K, et al. Distal left main coronary disease is a major predictor of outcome in patients undergoing percutaneous intervention in the drug-eluting stent era: an integrated clinical and angiographic analysis based on the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) registries. J Am Coll Cardiol. 2006;47:1530-7.
15. Palmerini T, Marzocchi A, Marrozzini C, Ortolani P, Saia F, Savini C, et al. Comparison between coronary angioplasty and coronary artery bypass surgery for the treatment of unprotected left main coronary artery stenosis (the Bologna Registry). Am J Cardiol. 2006;98:54-9
16. Price MJ, Cristea E, Sawhney N, Kao JA, Moses JW, Leon MB, et al. Serial angiographic follow-up of sirolimus-eluting stents for unprotected left main coronary artery revascularization. J Am Coll Cardiol. 2006;47:871-7.
17. Briguori C, Airoldi F, Chieffo A, Montorfano M, Carlino M, Massimo Sangiorgi G, et al. Elective versus provisional intraaortic balloon pumping in unprotected left main stenting. Am Heart J. 2006;152:565-72.
18. Han YL, Wang SL, Jing QM, Li Y, Zhang J, Ma YY, Luan B. Percutaneous coronary intervention for chronic total occlusion in 1263 patients: a single-center report. Chin Med J (Engl). 2006;119:1165-70.
19. Kaneda H, Saito S, Shiono T, Miyashita Y, Takahashi S, Domae H. Sixty-four-slice computed tomography-facilitated percutaneous coronary intervention for chronic total occlusion. Int J Cardiol. 2007;115(1):130-2.
20. Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MA, Kiemeneij F, et al. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II). A Randomized comparison of bare metal stent implantation with sirolimus-eluting stent for the treatment of coronary occlusions. Circulation. 2006;114:921-8.
21. Medina A, Suarez de Lezo J, Pan M. A new classification of coronary bifurcation lesions. Rev Esp Cardiol. 2006;59:183.
22. Pan M, Suárez de Lezo J, Medina A, Romero M, Delgado A, Segura J, et al. Ecografía intracoronaria durante el seguimiento en la valoración de stents liberadores de rapamicina para el tratamiento de las lesiones en bifurcación: implicaciones técnicas. Rev Esp Cardiol. 2005;58:1278-86.
23. Hoye A, Iakovou I, Ge L, Van Mieghem CA, Ong AT, Cosgrave J, et al. Long-term outcomes after stenting of bifurcation lesions with the «crush» technique: predictors of an adverse outcome. J Am Coll Cardiol. 2006;47:1949-58.
24. Moussa I, Costa RA, Leon MB, Lansky AJ, Lasic Z, Cristea E, et al. A prospective registry to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions using the «crush technique ». Am J Cardiol. 2006;97:1317-21.
25. Jiménez-Quevedo P, Sabate M, Angiolillo DJ, Costa MA, Alfonso F, Gómez-Hospital JA, et al. Vascular effects of sirolimus-eluting versus bare-metal stents in diabetic patients: three-dimensional ultrasound results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. J Am Coll Cardiol. 2006;47:2172-9.
26. Berenguer A, Mainar V, Bordes P, Valencia J, Gómez S. Efficacy of sirolimus-eluting stents in diabetics with complex coronary lesions. Rev Esp Cardiol. 2006;59:117-24.
27. Nallamothu BK, Bates ER, Herrin J, Wang Y, Bradley EH, Krumholz HM. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation. 2005;111:761-7.
28. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation. 2004;109:1223-5.
29. Herrmann HC. Transfer for primary angioplasty: the importance of time. Circulation. 2005;111:718-20.
30. Jacobs AK, Antman EM, Ellrodt G, Faxon DP, Gregory T, Mensah GA, et al. Recommendation to develop strategies to increase the number of ST-segment-elevation myocardial infarction patients with timely access to primary percutaneous coronary intervention. Circulation. 2006;113:2152-63.
31. Bassand JP, Danchin N, Filippatos G, Gitt A, Hamm C, Silber S, et al. Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology. Eur Heart J. 2005;26:2733-41.
32. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006;367:569-78.
33. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet. 2006;367:579-88.
34. Armstrong PW. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J. 2006;27:1530-8.
35. Laarman GJ, Suttorp MJ, Dirksen MT, Van Heerebeek L, Kiemeneij F, Slagboom T, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Eng J Med. 2006;355:1105-13.
36. Spaulding C, Henry P, Teiger E. Final results of the TYPHOON study: a multicenter, randomized trial comparing the use of sirolimus eluting stents to bare metal stents in primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2006;47:50B.
37. Kim W, Jeong MH, Kim KH, Sohn IS, Hong YJ, Park HW, et al. The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab: ReoPro)-coated stent in acute myocardial infarction. J Am Coll Cardiol. 2006;47:933-8.
38. Sutton AG, Campbell PG, Graham R, Price DJ, Gray JC, Grech ED, et al. A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction: the Middlesbrough Early Revascularization to Limit INfarction (MERLIN) trial. J Am Coll Cardiol. 2004;44:287-96.
39. Gershlick AH, Stephens-Lloyd A, Hughes S, Abrams KR, Stevens SE, Uren NG, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med. 2005;353:2758-68.
40. Steg PG, Francois L, Iung B, Himbert D, Aubry P, Charlier P, et al. Long-term clinical outcomes after rescue angioplasty are not different from those of successful thrombolysis for acute myocardial infarction. Eur Heart J. 2005;26:1831-7.
41. Antoniucci D. Rheolytic thrombectomy in acute myocardial infarction: The Florence Experience and Objectives of the Multicenter Randomized JETSTENT Trial. J Invasive Cardiol. 2006;18 Suppl C:32-4.
42. Chinnaiyan KM, Grines CL, O'Neill WW, Shah D, Raju A, Decker J, et al. Safety of AngioJet Thrombectomy in Acute ST-Segment Elevation Myocardial Infarction: A Large, Single-Center Experience. J Invasive Cardiol. 2006;18 Suppl C:17-21.
43. Sharma SK, Tamburrino F, Mares AM, Kini AS. Improved outcome with angiojet thrombectomy during primary stenting in acute myocardial infarction patients with high-grade thrombus. J Invasive Cardiol. 2006;18 Suppl C:8-11.
44. Sianos G, Papafaklis MI, Vaina S, Daemen J, Van Mieghem CA, Van Domburg RT, et al. Rheolytic thrombectomy in patients with ST-elevation myocardial infarction and large thrombus burden: the thoraxcenter experience. J Invasive Cardiol. 2006;18 Suppl C:3-7.
45. Ali A, Cox D, Dib N, Brodie B, Berman D, Gupta N, et al. Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study. J Am Coll Cardiol. 2006;48:244-52.
46. Kaltoft A, Bottcher M, Nielsen SS, Hansen HH, Terkelsen C, Maeng M, et al. Routine thrombectomy in percutaneous coronary intervention for acute ST-segment-elevation myocardial infarction: a randomized, controlled trial. Circulation. 2006;114:40-7.
47. Biondi-Zoccai G, Abbate A, Agostoni P, Testa L, Burzotta F, Lotrionte M, et al. Long-term benefits of an early invasive managment in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: a metaregression. Am Heart J. 2005;149:504-11.
48. Metha S, Cannon C, Fox K, Wallentin L, Boden W, Spacek R, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes. JAMA. 2005;293:2908-17.
49. De Winter R, Windhausen F, Cornel J, Dunselman P, Janus C, Bendermacher P, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med. 2005;353:1095-104.
50. Fox K, Poole-Wilson P, Clayton T, Henderson R, Shaw T, Wheatley D, et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet. 2005;366:914-20.
51. De Winter, on behalf of the ICTUS investigators. Early invasive versus selective management for acute coronary syndromes: three-year follow-up of the ICTUS trial. Presentado en el Congreso Europeo de Cardiología 2006. Barcelona 2-6 de septiembre. Disponible en: http://www.escardio.org/knowledge/ congresses/CongressReports/hotlinesandctus/708005_De+Winter.htm
52. Lagerqvist B, on behalf of the FRISC II investigators. Five years follow-up on the protective effects of an early invasive strategy in non-ST elevation acute coronary syndrome in the FRISC II study. Presentado en el Congreso Europeo de Cardiología 2006. Barcelona 2-6 septiembre. Disponible en: http://www.escardio.org/knowledge/congresses/CongressReports/ hotlinesandctus/708009_Lagerqvist.htm
53. Hoenig M, Doust J, Aroney C, Scott IS, Labianca S. Early invasive versus conservative strategies for unstable angina and non-ST-elevation myocardial infarction in the stent era. Cochrane Database Syst Rev. 2006;3:CD004815.
54. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556-65.
55. Mintz GS, Weissman NJ. Intravascular ultrasound in the drug-eluting stent era. J Am Coll Cardiol. 2006;48:421-9.
56. Hong MK, Mintz GS, Lee CW, Park DW, Choi BR, Park KH, et al. Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation. Eur Heart J. 2006;27:1305-10.
57. Nasu K, Tsuchikane E, Katoh O, Vince DG, Virmani R, Surmely JF, et al. Accuracy of in vivo coronary plaque morphology assessment: a validation study of in vivo virtual histology compared with in vitro histopathology. J Am Coll Cardiol. 2006;47:2405-12.
58. Valgimigli M, Rodríguez-Granillo GA, García-García HM, Malagutti P, Regar E, De JP, et al. Distance from the ostium as an independent determinant of coronary plaque composition in vivo: an intravascular ultrasound study based radiofrequency data analysis in humans. Eur Heart J. 2006;27:655-63.
59. Aoki J, Rodríguez-Granillo GA, Serruys PW. Emergent strategies in interventional cardiology. Rev Esp Cardiol. 2005;58: 962-73.
60. Rodriguez-Granillo GA, McFadden EP, Valgimigli M, Van Mieghem CA, Regar E, De Feyter PJ, et al. Coronary plaque composition of nonculprit lesions, assessed by in vivo intracoronary ultrasound radio frequency data analysis, is related to clinical presentation. Am Heart J. 2006;151:1020-4.
61. Sano K, Kawasaki M, Ishihara Y, Okubo M, Tsuchiya K, Nishigaki K, et al. Assessment of vulnerable plaques causing acute coronary syndrome using integrated backscatter intravascular ultrasound. J Am Coll Cardiol. 2006;47:734-41.
62. Kawasaki M, Bouma BE, Bressner J, Houser SL, Nadkarni SK, MacNeill BD, et al. Diagnostic accuracy of optical coherence tomography and integrated backscatter intravascular ultrasound images for tissue characterization of human coronary plaques. J Am Coll Cardiol. 2006;48:81-8.
63. Stamper D, Weissman NJ, Brezinski M. Plaque characterization with optical coherence tomography. J Am Coll Cardiol. 2006;47:C69-79.
64. Kume T, Akasaka T, Kawamoto T, Watanabe N, Toyota E, Neishi Y, et al. Assessment of coronary arterial plaque by optical coherence tomography. Am J Cardiol. 2006;97:1172-5.
65. Kume T, Akasaka T, Kawamoto T, Ogasawara Y, Watanabe N, Toyota E, et al. Assessment of coronary arterial thrombus by optical coherence tomography. Am J Cardiol. 2006;97:1713-7.
66. Manfrini O, Mont E, Leone O, Arbustini E, Eusebi V, Virmani R, et al. Sources of error and interpretation of plaque morphology by optical coherence tomography. Am J Cardiol. 2006;98:156-9.
67. Lindstaedt M, Yazar A, Germing A, Fritz MK, Holland-Letz T, Mugge A, et al. Clinical outcome in patients with intermediate or equivocal left main coronary artery disease after deferral of surgical revascularization on the basis of fractional flow reserve measurements. Am Heart J. 2006;152:156-9.
68. Jiménez-Navarro MF, Alonso-Briales J, Hernández- García JM, Curiel E, Kuhlmorgen B, Gómez-Doblas JJ, et al. Usefulness of fractional flow reserve in multivessel coronary artery disease with intermediate lesions. J Interv Cardiol. 2006;19:148-52.
69. Samady H, Lepper W, Powers ER, Wei K, Ragosta M, Bishop GG, et al. Fractional flow reserve of infarct-related arteries identifies reversible defects on noninvasive myocardial perfusion imaging early after myocardial infarction. J Am Coll Cardiol. 2006;47:2187-93.
70. Mauri L, Orav EJ, Candia SC, Cutlip DE, Kuntz RE. Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation. 2005;112:2833-9.
71. Dixon SR, Grines CL, O'Neill WW. The year in Interventional Cardiology. J Am Coll Cardiol. 2006;47:1689-706.
72. Daemen J, Ong AT, Stefanini GG, Tsuchida K, Spindler H, Sianos G, et al. Three-Year Clinical Follow-Up of the Unrestricted Use of Sirolimus-Eluting Stents as Part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) Registry. Am J Cardiol. 2006;98:895-901.
73. Sabaté M, Jiménez-Quevedo P, Angiolillo DJ, Gómez-Hospital JA, Alfonso F. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients. The Diabetes and Sirolimus-Eluting Stent (DIABETES) trial. Circulation. 2005;112:2175-83.
74. Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus. The TAXUS-IV trial. J Am Coll Cardiol. 2005;45:1172-9.
75. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al. Comparison of a polymer based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease. A randomized controlled trial. JAMA. 2005;294:1215-23.
76. Dawkins KD, Grube E, Guagliumi G, Banning A, Zmudka K, Colombo A, et al. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation. 2005;112:3306-13.
77. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006;114:798-806.
78. Morice MC. A prospective randomized trial of a tacrolimus-eluting stent compared to a carbon-coated stent in patients with coronary artery disease (JUPITER-II). Presented at Transcatheter Cardiovascular Therapeutics 2005, Washington, DC, octubre 2005.
79. Serruys PW. SPIRIT II Study: a clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo, native coronary artery lesions. Presentado en el Congreso de la Sociedad Europea de Cardiología, Barcelona 2-6 de septiembre 2006. Disponible en http://www.escardio.org/knowledge/congresses/CongressReports/hotlinesandctus/ 709005_Serruys.htm
80. Kastrati A, Dibra A, Eberle S, Mehilli J, Suárez de Lezo J, Goy JJ, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease. Meta-analysis of randomized trials. JAMA. 2005;294:819-25.
81. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA. 2006;295:895-904
82. Serruys PW, Morice MC, Colombo A, Meier B, Tamburino C, Guagliumi G, et al. Prospective randomized multicenter head to head comparison of the sirolimus-eluting stent and the paclitaxel-eluting stent: 2-year outcome of REALITY trial. Presentado en congreso de la Sociedad Europea de Cardiología, Barcelona, septiembre 2006. Disponible en: http://www.escardio.org/knowledge/congresses/abol/presentation?id=41574
83. Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, et al. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation. 2006;113:2293-300.
84. Elezi S, Dibra A, Mehilli J, Pache J, Wessely R, Schömig A, et al. Vessel size and outcome after coronary drug-eluting stent placement results from a large cohort of patients treated with sirolimus-or paclitaxel-eluting stents. J Am Coll Cardiol. 2006;48:1304-9.
85. Ong AT, Serruys PW, Aoki J, Hoye A, Van Mieghem CA, Rodríguez- Granillo GA, et al. The unrestricted use of paclitaxel-versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol. 2005;45:1135-41.
86. Saia F, Piovaccari G, Manari A, Santarelli A, Benassi A, Aurier E, et al. Clinical Outcomes for sirolimus-eluting stents and polymer-coated paclitaxel-eluting stents in daily practice. Results from a large multicenter registry. J Am Coll Cardiol. 2006;48:1312-8.
87. Kuchulakanti PK, Chu WW, Torguson R, Clavijo L, Wolfram R, Mishra S, et al. Sirolimus-eluting stents versus Paclitaxel-eluting stents in the treatment of coronary artery disease in patients with diabetes mellitus. Am J Cardiol. 2006;98:187-92.
88. Lakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-30.
89. Moreno R, Fernández C, Hernández R, Alfonso F, Angiolillo D, Sabaté M, et al. Drug-eluting stent thrombosis. Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005;45:954-9.
90. Pfisterer ME, Kaiser CA, Bader F, Brunner-La Rocca HP, Bonetti PO, Buser PT. Late clinical events related to late stent thrombosis after stopping clopidogrel: prospective randomized comparison between drug-eluting vs base-metal stenting. Presentado en el American College of Cardiology 55th Annual Scientific Session. Atlanta, marzo 2006. Abstract 422-11.
91. Camenzind E. A meta-analysis of first generation drug eluting stents: including both first generation drug eluting stent extent of both mortality and Q-wave Myocardial Infarction in comparison to bare metal stents. Presentado en el Congreso Europeo de Cardiología, Barcelona 2-6 de Septiembre 2006. Disponible en: http://www.escardio.org/knowledge/congresses/CongressReports/ hotlinesandctus/707009_Camenzind.htm
92. Morice MC. A randomized study with the sirolimus coated BXTM velocityTM balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. The RAVEL study. Presentado en el Congreso Europeo de Cardiología, Barcelona 2-6 de Septiembre 2006. Disponible en: http://www.escardio.org/knowledge/congresses/CongressReports/hotline-sandctus/ 710007_Morice.htm
93. Wenaweser P, Tsuchida K, Vaina S, Abrecht L, Daemen J, Morger C, et al. Late stent thrombosis following drug-eluting stent implantation: data from a large, two-institutional cohort study. Presentado en el Congreso Europeo de Cardiología, Barcelona 2-6 de septiembre 2006. Disponible en: http://www.escardio.org/knowledge/congresses/abol/presentation?id=39157
94. Kastrati A, Mehilli J, Neumann F, Dotzer F, Ten Berg J, Bollwein H, et al. Intracoronary stenting and antithrombotic: regimen rapid early action for coronary treatment 2 (ISAR-REACT 2) trial investigators. JAMA. 2006;295:1531-8.
95. Galache Osuna JG, Sánchez-Rubio J, Calvo I, Diarte JA, Lukic A, Placer LJ. Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomized controlled trial. Rev Esp Cardiol. 2006;59:567-74.
96. Pérez de Prado A, Fernández-Vázquez F, Cuenllas-Ramón JC, Gibson CM. Angiografía coronaria; más allá de la anatomía coronaria. Rev Esp Cardiol. 2006;59:596-608.
97. Stone G, on behalf of the ACUITY investigators. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. 55th Scientific Sessions of the American College of Cardiology, March 12, 2006; Atlanta.
98. Gibson M, Morrow D, Murphy S, Palabrica T, Jennigs L, Stone P, et al. A randomised trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflamamation among antiplatelet and antithrombotic agents. The PROTECT-TIMI 30 trial. J Am Cardiol. 2006;47:2364-73.
99. De Luca, Suryapranata H, Stone G, Antoniucci D, Tcheng J, Neumann F, et al. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. J Am Coll Cardiol. 2006;47:685-6G.
100. Ince H, Petzsch M, Klein HD, Eckard H, Rehders T, Burska D, et al. Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction. Final 1-year results of the front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by granulocyte colony-stimulating factor (FIRSTLINE-AMI) trial. Circulation. 2005;112 Suppl I:73-80.
101. Ripa RS, Jorgensen E, Yongzhong W, Thune JJ, Nilsson JC, Sondergaard L, et al. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction. Result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation. 2006;113:1983-92.
102. Steinwender C, Hofmann R, Kammler J, Kypta A, Pichler R, Maschek W, et al. Effects of peripheral blood stem cell mobilization whit granulocyte-colony stimulating factor and their transcoronary transplantation after primary stent implantation for acute myocardial infarction. Am Heart J. 2006;151:1296-13.
103. Kang HJ, Lee HY, Na SN, Chang SA, Park KW, Kim HK, et al. Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction. The MAGIC Cell-3-DES randomized, controlled trial. Circulation. 2006;114 Suppl I:145-51.
104. Schächinger V, Erbs S, Elsässer A, Haberbosh W, Hambrecht R, Hölschermann H, et al; for the REPAIR-AMI investigators. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355:1210-21.
105. Lunde K, Solheim S, Aakhus S, Arnesen H, Abdenoor M, Egeland T, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006;355:1199-209.
106. Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet W, et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet. 2006;367:113-21.
107. Hendrikx M, Hensen K, Clijsters C, Jongen H, Koninckx R, Bijnens E, et al. Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation. Results from a randomized controlled clinical trial. Circulation. 2006;114 Suppl I:101-7.
108. Hagège A, Marolleaou JP, Vilquin JT, Alhéritière A, Peyrard S, Duboc D, et al. Skeletal myoblast transplantation in ischemic heart failure. Long-term follow-up of the first phase I cohort of patients. Circulation. 2006;114 Suppl:108-14.
109. Siminiak T, Fiszer D, Jerzykowska O, Grygielska B, Rozwadowska N, Kalmucki P, et al. Percutaneous trans-coronary-venous transplantation of autologous skeletal myoblasts in the treatment of post-infarction myocardial contractility impairment: the POZAN trial. Eur Heart J. 2005;26:1188-95.
110. Webb JG, Chandavimol M, Thompson CR, Ricci DR, Carere RG, Munt BI, et al. Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation. 2006;113:842-50.
111. Lichtenstein SV, Cheung A, Ye J, Thompson CR, Carere RG, Pasupati S, et al. Transapical transcatheter aortic valve implantation in humans: initial clinical experience. Circulation. 2006; 114:591-6.
112. Grube E, Laborde JC, Zickmann B, Gerckens U, Felderhoff T, Sauren B, et al. First report on a human percutaneous transluminal implantation of a self-expanding valve prosthesis for interventional treatment of aortic valve stenosis. Catheter Cardiovasc Interv. 2005;66:465-9.
113. Paniagua D, Condado JA, Besso J, Velez M, Burger B, Bibbo S, et al. First human case of retrograde transcatheter implantation of an aortic valve prosthesis. Tex Heart Inst J. 2005;32:393-8.
114. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie S, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Circulation. 2006;113:e409-49.
115. Sastry S, Riding G, Morris J, Taberner D, Cherry N, Heagerty A, et al. Young Adult Myocardial Infarction and Ischemic Stroke The Role of Paradoxical Embolism and Thrombophilia (The YAMIS Study). J Am Coll Cardiol. 2006;48:686-91.
116. Meissner I, Khandheria BK, Heit JA, Petty GW, Sheps SG, Schwartz GL, et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am Coll Cardiol. 2006;47:440-5.
117. Bonati LH, Kessel-Schaefer A, Linka AZ, Buser P, Wetzel SG, Radue EW, et al. Diffusion-weighted imaging in stroke attributable to patent foramen ovale: significance of concomitant atrial septum aneurysm. Stroke. 2006;37:2030-4.
118. Thomson JD. Percutaneous PFO closure, further data but many unanswered questions. Eur Heart J. 2006;27:258-9.
119. Hara H, Virmani R, Ladich E, Mackey-Bojack S, Titus J, Reisman M, et al. Patent foramen ovale: current pathology, pathophysiology, and clinical status. J Am Coll Cardiol. 2005;46: 1768-76.
120. Rigatelli G, Braggion G, Chinaglia M, Cardaioli P, Roncon L, Giordan M, et al. Setting up a multidisciplinary program for management of patent foramen ovale-mediated syndromes. J Interv Cardiol. 2006;19:264-8